Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc.
Explore linked clinical trials.6 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Long-term Study of KT-621 Administered Orally to Participants With Asthma Previously Enrolled in a KT-621 Asthma Study | Hypersensitivity, Immediate, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Respiratory Hypersensitivity, asthma, bronchial disorder, disease, immune system disorder, lung disorder, obstructive lung disease, respiratory system disorder | Recruiting | Phase 2 | 2026-10-07 | NCT07677059 | |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Eosinophilia, Hemic and Lymphatic Diseases, hematologic disorder, hypereosinophilic syndrome, leukocyte disorder, lung disorder, pulmonary eosinophilia, respiratory system disorder | Recruiting | Phase 2 | 2026-10-06 | NCT07323654 | |
| A Study of KT-621 Administered Orally to Participants With Moderate to Severe Atopic Dermatitis | Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hypersensitivity, Immediate, Skin Diseases, Eczematous, Skin and Connective Tissue Diseases, atopic eczema, dermatitis, hereditary disease, hereditary skin disorder, immune system disorder, skin disorder | Active, not recruiting | Phase 2 | 2026-10-06 | NCT07217015 | |
| A Study to Evaluate Different Oral Formulations of KT-621 | Healthy Participants | Recruiting | Phase 1 | 2026-09-16 | NCT07823205 | |
| SAR447971 First-in-human Study | Skin and Connective Tissue Diseases, hidradenitis, skin disorder, sweat gland disorder | Recruiting | Phase 1 | 2026-06-05 | NCT07629336 | |
| First-in-human Study of Orally Administered KT-579 in Healthy Adult Participants | Healthy Participants | Recruiting | Phase 1 | 2026-02-27 | NCT07412288 |